PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of epigLink to Publisher's site
 
Epigenetics. 2011 July; 6(7): 892–894.
Published online 2011 July 1. doi:  10.4161/epi.6.7.15544
PMCID: PMC3154430

The role of holocarboxylase synthetase in genome stability is mediated partly by epigenomic synergies between methylation and biotinylation events

Abstract

Holocarboxylase synthetase (HLCS) catalyzes the covalent binding of biotin to histones. Biotinylated histones are gene repression marks and are particularly enriched in long terminal repeats, telomeres and other repeat regions. The effects of HLCS in gene regulation are mediated by its physical interactions with chromatin proteins such as histone H3, DNMT1, MeCP2 and EHMT-1. It appears that histone biotinylation depends on prior methylation of cytosines. De-repression of long terminal repeats in biotin- or HLCS-deficient cell cultures and organisms is associated with genome instability.

Key words: biotin, DNMT1, EHMT-1, genome stability, histone, holocarboxylase synthetase, MeCP2, methylation

Background

The human holocarboxylase synthetase (HLCS) gene was characterized in 1994.1 Originally it was believed that the role of HLCS is limited to that as a biotin:carboxylase ligase, catalyzing the covalent binding of the vitamin biotin to 3-methylcrotonyl-CoA carboxylase, propionyl-CoA carboxylase, pyruvate carboxylase and acetyl-CoA carboxylases 1 and 2 in humans.2,3 Subsequently, it was demonstrated that HLCS and its microbial ortholog BirA can also biotinylate histones.4,5 To date, at least five biotinylation sites have been identified in histones H3 [lysine (K)-4, K9, K18 and probably K23] and H4 (K8, K12 and probably K16).4,6,7 K9 and K13 in histone H2A might also be biotinylated,8 but the abundance of these two marks appears to be very low.9 Studies with synthetic HLCS substrates provide unambiguous evidence that biotinylation of histones by HLCS is a substrate-specific process,10 contrary to claims that histone biotinylation is a random event.11

Biotinylation of Histones is a Real Epigenetic Mark

The existence of biotinylated histones was recently questioned by Healy et al.12 but three independent laboratories, in addition to ours, confirmed that biotinylation is a natural histone modification.1315 These studies included analysis of histone biotinylation by mass spectrometry and suggested that, at least in Candida albicans, up to 50% of histones might be biotinylated.14 In contrast, histone biotinylation is a comparably rare event in humans (<0.1% of histones are biotinylated),15 but the abundance of an epigenetic mark is no marker for its importance. For example, serine-14 phosphorylation in histone H2B and histone poly(ADP-ribosylation) are detectable only after induction of apoptosis and major DNA damage, respectively, but the role of these epigenetic marks in cell death is unambiguous.16,17 The abundance of histone biotinylation marks is much greater in confined genomic loci compared with bulk histones. For example, about one out of three molecules of histone H4 is biotinylated at K12 in telomeric chromatin.18

Cellular Distribution of HLCS and Regulation of Expression

Consistent with its role as carboxylase and histone biotinyl ligase, HLCS can be found in both extranuclear and nuclear compartments.8,19,20 Nuclear HLCS is associated with chromatin and the nuclear lamina.19,20 The binding of HLCS to chromatin is mediated by physical interactions with histones H3 and H4;5 the recruitment of HLCS to particular loci is probably mediated by interactions between HLCS and other chromatin proteins (see below). HLCS binding sites in chromatin have been mapped by using both DNA adenosyl methyltransferase technology and chromatin immunoprecipitation assays.2123

Our knowledge of HLCS regulation is limited to the following observations: (1) Both the abundance of HLCS mRNA and the nuclear translocation of HLCS depend on biotin.22 (2) The human HLCS promoter has been tentatively identified24 but not yet characterized in great detail. (3) The expression of HLCS is repressed by miR-539.25

Phenotypes of HLCS Deficiency

HLCS deficiency causes severe phenotypes, consistent with the key roles that HLCS plays in intermediary metabolism and gene regulation. No living HLCS null individual has ever been reported, suggesting embryonic lethality. HLCS knockdown studies (~30% residual activity) produced phenotypes such as decreased life span and heat resistance in Drosophila melanogaster,20 and aberrant gene regulation in human cell lines.22 Low levels of biotinylated proteins have been linked to de-repression of retrotransposons and chromosomal abnormalities as described below in reference 21.

Numerous mutations in the human HLCS gene have been identified and characterized at both the enzymatic and clinical level; these mutations cause a substantial decrease in HLCS activity.26,27 Unless diagnosed and treated early, HLCS deficiency appears to be uniformly fatal.28 Three independent cancer and patent databases correlate HLCS loss or mutation with human tumors.2931

Histone Biotinylation is a Repression Mark

All known species of biotinylated histones are gene repression marks.21,22,32,33 Atomic force microscopy studies suggest that nucleosomal condensation increases in response to biotinylation of K12 and possibly other residues, in histone H4.34 Biotinylation marks such as K-12-biotinylated histone H4 (H4K12bio) colocalize with repression marks such as methylated cytosines and K9-dimethylated histone H3 (H3K9me2).21,22,32,33

Debiotinylation of Histones

The binding of biotin to histones is a reversible process, but the identity of the histone debiotinylase is uncertain. Circumstantial evidence has been provided that biotinidase has histone debiotinidase activity.35,36 This notion is consistent with the classical role of biotinidase as a biotin-ε-lysine hydrolase.37 The hydrolysis of the biotin-ε-lysine bond by biotinidase is a reversible reaction and the equilibrium can be shifted toward the binding of biotin to histones by providing high concentrations of biotin-ε-lysine in vitro.6,38

Epigenomic Synergies between Biotinylation and Methylation Marks

Depletion of histone biotinylation can be achieved by biotin depletion or HLCS knockdown and causes deregulation of genes.7,22,32,33 Consistent with this notion, depletion of histones biotinylation de-regulates long-terminal repeats (LTRs). The production of viral particles, the frequency of retrotransposition events, and the number of chromosomal abnormalities increase when LTRs are de-repressed by biotin depletion or HLCS knockdown in cell cultures, humans and Drosophila melanogaster.21 Retrotransposition events may cause cancer,3945 and de-repression of retroelements by biotin depletion and HLCS deficiency unambiguously links biotin status with cancer risk.

Nutrients may have synergistic effects in gene regulation by epigenomic mechanisms. Evidence suggests cross-talk between biotinylation and methylation marks in maintaining genome stability.21,22,32,33 For example, histone biotinylation is substantially impaired when cytosine methylation marks are erased by treating cells with 5-aza-2′deoxycytidine;21 in contrast, depletion of biotinylated histones does not affect cytosine methylation, suggesting that methylation is the primary loading factor. The local enrichment of another repression mark, H3K9me2, depends on prior enrichment of H4K12bio.21,22,32,33 Importantly, preliminary evidence suggests that HLCS physically interacts with the maintenance DNA methyltransferase DNMT1, the methyl-CpG-binding domain protein 2 (MeCP2) and the H3K9 methyltransferase EHMT-1 (Xue J, et al. unpublished; Li Y, et al. unpublished).

Causal links between histone biotinylation and the teratogenic effects of biotin deficiency remain to be demonstrated.46,47 Note that the human biotin requirement is unknown and that recommendations for biotin intake are based solely on the typical intake of biotin in the general, apparently healthy, population.48 This approach is flawed in the case of biotin where dietary intake data are only crude estimates. Currently, no studies are available that quantified biotin in foods by using chemically specific assays,49 and it is not clear whether intake estimates exceed or underestimate the true biotin intake. Also, the “normal state” is defined by using biotin-dependent carboxylases or urinary metabolites as markers, while ignoring the apparently subtle changes occurring at the chromatin level.

Acknowledgements

A contribution of the University of Nebraska Agricultural Research Division, supported in part by funds provided through the Hatch Act. Additional support was provided by NIH grants DK063945, DK077816, DK082476 and ES015206, and USDA CSREES grant 2006-35200-17138.

Abbreviations

DNMT1
DNA methyltransferase 1
EHMT-1
euchromatic histone methyltransferase
H3K9me2
K9-dimethylated histone H3
H3K9me3
H4K12bio, K12-biotinylated histone H4
HLCS
holocarboxylase synthetase
K
lysine
LTR
long terminal repeat
MeCP2
methyl-CpG-binding domain protein 2

References

1. Suzuki Y, Aoki Y, Ishida Y, Chiba Y, Iwamatsu A, Kishino T, et al. Isolation and characterization of mutations in the human holocarboxylase synthetase cDNA. Nat Genet. 1994;8:122–128. [PubMed]
2. Leon-Del-Rio A, Leclerc D, Akerman B, Wakamatsu N, Gravel RA. Isolation of a cDNA encoding human holocarboxylase synthetase by functional complementation of a biotin auxotroph of Escherichia coli. Proc Natl Acad Sci USA. 1995;92:4626–4630. [PubMed]
3. Campeau E, Gravel RA. Expression in Escherichia coli of N- and C-terminally deleted human holocarboxylase synthetase. Influence of the N-terminus on biotinylation and identification of a minimum functional protein. J Biol Chem. 2001;276:12310–12316. [PubMed]
4. Kobza K, Sarath G, Zempleni J. Prokaryotic BirA ligase biotinylates K4, K9, K18 and K23 in histone H3. BMB Reports. 2008;41:310–315. [PMC free article] [PubMed]
5. Bao B, Pestinger V, HY I, Borgstahl GEO, Kolar C, Zempleni J. Holocarboxylase synthetase is a chromatin protein and interacts directly with histone H3 to mediate biotinylation of K9 and K18. J Nutr Biochem. 2011;22:470–475. [PMC free article] [PubMed]
6. Camporeale G, Shubert EE, Sarath G, Cerny R, Zempleni J. K8 and K12 are biotinylated in human histone H4. Eur J Biochem. 2004;271:2257–2263. [PubMed]
7. Kobza K, Camporeale G, Rueckert B, Kueh A, Griffin JB, Sarath G, Zempleni J. K4, K9 and K18 in human histone H3 are targets for biotinylation by biotinidase. FEBS J. 2005;272:4249–4259. [PMC free article] [PubMed]
8. Chew YC, Camporeale G, Kothapalli N, Sarath G, Zempleni J. Lysine residues in N- and C-terminal regions of human histone H2A are targets for biotinylation by biotinidase. J Nutr Biochem. 2006;17:225–233. [PMC free article] [PubMed]
9. Stanley JS, Griffin JB, Zempleni J. Biotinylation of histones in human cells: effects of cell proliferation. Eur J Biochem. 2001;268:5424–5429. [PubMed]
10. Hassan YI, Moriyama H, Zempleni J. The polypeptide Syn67 interacts physically with human holocarboxylase synthetase, but is not a target for biotinylation. Arch Biochem Biophys. 2009;495:35–41. [PMC free article] [PubMed]
11. Healy S, Heightman TD, Hohmann L, Schriemer D, Gravel RA. Nonenzymatic biotinylation of histone H2A. Protein Sci. 2009;18:314–328. [PubMed]
12. Healy S, Perez-Cadahia B, Jia D, McDonald MK, Davie JR, Gravel RA. Biotin is not a natural histone modification. Biochim Biophys Acta. 2009;1789:719–733. [PubMed]
13. Takechi R, Taniguchi A, Ebara S, Fukui T, Watanabe T. Biotin deficiency affects the proliferation of human embryonic palatal mesenchymal cells in culture. J Nutr. 2008;138:680–684. [PubMed]
14. Ghosh S. Physiology, regulation and pathogenesis of nitrogen metabolism in opportunistic fungal pathogen Candida albicans. University of Nebraska-Lincoln, School of Biological Sciences: Lincoln, NE; 2009. Ph.D. thesis. [advisor: Ken Nickerson]
15. Bailey LM, Ivanov RA, Wallace JC, Polyak SW. Artifactual detection of biotin on histones by streptavidin. Anal Biochem. 2008;373:71–77. [PubMed]
16. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell. 2003;113:507–517. [PubMed]
17. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal. Genes Dev. 2005;19:1951–1967. [PubMed]
18. Wijeratne SS, Camporeale G, Zempleni J. K12-biotinylated histone H4 is enriched in telomeric repeats from human lung IMR-90 fibroblasts. J Nutr Biochem. 2010;21:310–316. [PMC free article] [PubMed]
19. Narang MA, Dumas R, Ayer LM, Gravel RA. Reduced histone biotinylation in multiple carboxylase deficiency patients: a nuclear role for holocarboxylase synthetase. Hum Mol Genet. 2004;13:15–23. [PubMed]
20. Camporeale G, Giordano E, Rendina R, Zempleni J, Eissenberg JC. Drosophila holocarboxylase synthetase is a chromosomal protein required for normal histone biotinylation, gene transcription patterns, lifespan and heat tolerance. J Nutr. 2006;136:2735–2742. [PMC free article] [PubMed]
21. Chew YC, West JT, Kratzer SJ, Ilvarsonn AM, Eissenberg JC, Dave BJ, et al. Biotinylation of histones represses transposable elements in human and mouse cells and cell lines, and in Drosophila melanogaster. J Nutr. 2008;138:2316–2322. [PMC free article] [PubMed]
22. Gralla M, Camporeale G, Zempleni J. Holocarboxylase synthetase regulates expression of biotin transporters by chromatin remodeling events at the SMVT locus. J Nutr Biochem. 2008;19:400–408. [PMC free article] [PubMed]
23. Singh D, Pannier AK, Zempleni J. Identification of holocarboxylase synthetase chromatin binding sites using the DamID technology. Anal Biochem. 2011;413:55–59. [PMC free article] [PubMed]
24. Warnatz HJ, Querfurth R, Guerasimova A, Cheng X, Haas SA, Hufton AL, et al. Functional analysis and identification of cis-regulatory elements of human chromosome 21 gene promoters. Nucleic Acids Res. 2010;38:6112–6123. [PMC free article] [PubMed]
25. Bao B, Rodriguez-Melendez R, Wijeratne SS, Zempleni J. Biotin regulates the expression of holocarboxylase synthetase in the miR-539 pathway in HEK-293 cells. J Nutr. 2010;140:1546–1551. [PubMed]
26. Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the holocarboxylase synthetase gene HLCS. Human Mutation. 2005;26:285–290. [PubMed]
27. National Center for Biotechnology Information, author. Online Mendelian Inheritance in Man. National Center for Biotechnology Information; [7/21/2008]. http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim.
28. Thuy LP, Belmont J, Nyhan WL. Prenatal diagnosis and treatment of holocarboxylase synthetase deficiency. Prenat Diagn. 1999;19:108–112. [PubMed]
29. UniProt, author. UniProtKB. [3/26/2010]. www.uniprot.org/uniprot/P50747.
30. Massague J, Bos P. Metastasis promoting genes and proteins. [3/26/2010]. www.faqs.org/patents/app/20100029748.
31. Institute for Biomedical Technologies, author. Genes-to-system breast cancer database. [3/26/2010]. www.itb.cnr.it/breastcancer/php/showMostCorrelated.php?id = 6664.
32. Camporeale G, Oommen AM, Griffin JB, Sarath G, Zempleni J. K12-biotinylated histone H4 marks heterochromatin in human lymphoblastoma cells. J Nutr Biochem. 2007;18:760–768. [PMC free article] [PubMed]
33. Pestinger V, Wijeratne SSK, Rodriguez-Melendez R, Zempleni J. Novel histone biotinylation marks are enriched in repeat regions and participate in repression of transcriptionally competent genes. J Nutr Biochem. 2011;22:328–333. [PMC free article] [PubMed]
34. Filenko NA, Kolar C, West JT, Hassan YI, Borgstahl GEO, Zempleni J, Lyubchenko YL. The role of histone H4 biotinylation in the structure and dynamics of nucleosomes. PLoS ONE. 2011;6:16299. [PMC free article] [PubMed]
35. Ballard TD, Wolff J, Griffin JB, Stanley JS, Calcar Sv, Zempleni J. Biotinidase catalyzes debiotinylation of histones. Eur J Nutr. 2002;41:78–84. [PubMed]
36. Chew YC, Sarath G, Zempleni J. An avidin-based assay for quantification of histone debiotinylase activity in nuclear extracts from eukaryotic cells. J Nutr Biochem. 2007;18:475–481. [PMC free article] [PubMed]
37. Wolf B. Biotinidase: its role in biotinidase deficiency and biotin metabolism. J Nutr Biochem. 2005;16:441–445. [PubMed]
38. Hymes J, Fleischhauer K, Wolf B. Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. Biochem Mol Med. 1995;56:76–83. [PubMed]
39. Fan H. A new human retrovirus associated with prostate cancer. Proc Natl Acad Sci USA. 2007;104:1449–1450. [PubMed]
40. Kazazian H, Jr, Moran JV. The impact of L1 retrotransposons on the human genome. Nat Genet. 1998;19:19–24. [PubMed]
41. Smit AF. Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr Opin Genet Dev. 1999;9:657–663. [PubMed]
42. Darai-Ramqvist E, Sandlund A, Muller S, Klein G, Imreh S, Kost-Alimova M. Segmental duplications and evolutionary plasticity at tumor chromosome break-prone regions. Genome Res. 2008;18:370–379. [PubMed]
43. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455. [PubMed]
44. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–153. [PubMed]
45. Check E. Cancer fears cast doubts on future of gene therapy. Nature. 2003;421:678. [PubMed]
46. Watanabe T. Teratogenic effects of biotin deficiency in mice. J Nutr. 1983;113:574–581. [PubMed]
47. Mock DM. Marginal biotin deficiency is common in normal human pregnancy and is highly teratogenic in mice. J Nutr. 2009;139:154–157. [PubMed]
48. National Research Council, author. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, DC: National Academy Press; 1998. [PubMed]
49. Zempleni J, Mock DM. Biotin. In: Song WO, Beecher GR, editors. Modern Analytical Methodologies on Fat and Water-Soluble Vitamins. New York, NY: Wiley & Sons, Inc; 2000. pp. 389–409.

Articles from Epigenetics are provided here courtesy of Landes Bioscience